A Canada-based investment firm that was founded in 2000 has two Health Tech Venture funds that invested in a total of 26 companies, mostly in Canada. The firm is currently in the process of raising its third fund. The firm invests in the health technology sector, especially medical technology and digital health. The second fund focuses on pre and post Series A investments with the ability to do follow-on funding. The investment size can range from $100K to over $1M and up to $2-4M with follow-on funding. The capital structure is flexible, especially as they are currently raising their third fund. The firm typically co-invests and will lead investments depending on the occasion and size of the round. Investment can be in form of equity, whereas convertible loan and other capital structures will be considered. The new fund looks to invest in 10-20 companies. The firm focuses on companies based in Canada, but it will also look at opportunities in the US. The firm’s investment activity has catalyzed over $200M of investment in the Canadian venture capital space.

In the life sciences, the firm is currently looking for new investments in the medical technology, diagnostics, digital health, AI applications in healthcare, surgical robotics and healthcare IT sectors with a particular interest in medical devices with a software component. The firm is interested in all classes of medical devices and is indication agnostic. The firm is focused on preclinical to clinical stage technology and is focused on technology that requires an FDA regulatory pathway. The firm will consider therapeutics companies from time-to-time, however, therapeutics is not the firm’s focus. Historically, the firm was active in a company developing blood-testing platform for infectious diseases.

The firm focuses on investments in private companies with an experienced management team and growth potential. The firm will take a board seat based on case-by-case basis, though is not the requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Vancouver-based venture capital firm actively invests in health technology, sports technology, fitness, and nutrition businesses. The firm is an early-stage investor and focuses on investing in Seed to Series A rounds. The firm makes initial investments up to $100K through equity or convertible notes and will make 2-4 investments per year. The firm is raising a new fund that will focus on companies along the Pacific Coast of the USA and across Canada, but currently focuses on investing in Canada-based companies. With the launch of the new venture fund, the firm will invest up to $500k in first rounds.

The firm is dedicated to investing in preventative health and proactive technology solutions that optimize health, activity and longevity. As social impact and technology investors, the firm is committed to the development of technologies, products and services that both enhance and promote an individual’s ability to stay optimally healthy and active over an entire lifetime.

The firm focuses on innovative health technologies including digital health, mobile health, sport technology, wearable technology, and those that help with chronic disease management and corporate wellness initiatives. The firm is very interested in consumer-facing technologies that can enhance health and wellness, quality of care, as well as technologies that could be used in developing preventative health strategies and solutions. The firm does not have minimum revenue requirements and will consider companies in their earliest stages as long as they demonstrate high growth potential. The firm will not consider therapeutics or diagnostic companies. Medical devices subject to a 510k approval process will be considered.

The firm seeks to invest in private companies developing technologies that positively impact health and wellness. The firm can work with all types of management teams with flexibility, although strong experience and a successful track record is a plus. The firm works closely with their portfolio companies and will provide needed expertise, including access to an international network of strategic advisors to support their growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A cross-border venture capital group based out of Toronto, Ontario is currently expanding into the healthcare space. The firm is currently seeking to make 1-2 investments within the healthcare space in the next 2 quarters. The firm prefers early stage investments from seed extension to series B, but can go up to series C. The firm can move quicker on small investments but slower for larger sized investments if syndication with Chinese investors is required. The firm does not typically lead investments and will consider opportunities within the US and Canada. The firm focuses on companies that have a strong China angle as they can provide help with entry into the Chinese market, with soft landings via their resources in China. The firm is particularly interested in platform technologies with strong, protectable IP with a high difficulty to replicate.

The firm is looking for opportunities within the medical device and digital health space. The firm prefers platform technologies that are applicable across multiple indications. The firm is opportunistic and has no preference towards indication. The firm has recently invested in an analytical device company that seeks to help research labs develop new therapeutics. For digital health companies, the firm prefers technologies that are applicable and deployable in China, while not easily duplicated. The firm prefers to invest in companies with some commercialization or are close to commercialization, but at minimal with market validation.

The firm prefers management teams with a strong scientific background and has an interest in expanding into China. The firm prefers to take a board seat in companies that currently lack a China expert so they can help the company with their expertise in working in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large real-estate company based in Canada looking to expand their investments into the healthcare field. The firm is looking to invest $4-5 million into various startups in the upcoming year, seeking opportunities at the Seed to Series A range. The firm is willing to both lead and follow on investments they make and are looking for opportunities solely within the US and Canada.

The firm is looking for opportunities within the Medical Device, Digital Health, Diagnostics, and Biotech R&D Spaces. Specifically, the firm is looking for technologies that can help physicians. Examples of such technologies include: telemedicine, clinical trial services for physicians, and digital health solutions to help patient engagement. The firm is also interested in new medical devices and diagnostic technologies that are in the clinical trial stage.

The firm is looking for a strong management team who has a strong vision and development plan for the technology of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm based in Spain raised a EUR 200 million fund to make stage agnostic life science deals, investing from early stages to pre-IPO. The firm prefers to lead rounds, particularly in late-stage opportunities. The firm is currently focused on opportunities in Europe. The firm may syndicate international opportunities with US investors. The firm typically reserves EUR 12-15 million per portfolio company.

The firm invests opportunistically in next wave healthcare technologies, including therapeutics, digital health, and medical devices. The firm will also consider diagnostic opportunities on occasion. The firm will invest at any stage of development.

The firm invests globally, but focuses on Europe and prefers to invest in companies with a Spain angle, such as IP or founders from Spain.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture fund based in Canada and backed by a major financial institution in Europe is investing from a new $125 million evergreen fund closed in 2017. The firm looks for companies located in Canada and the United States, with preference given to companies located close to Montreal. The firm makes equity investments in progressive stages, ranging up to $7m and typically leads the round – although the firm is open to co-investing. The firm focuses on companies from early revenue stage all the way up to expansion stage. The firm can help provide portfolio companies with access to the European market.

The firm is interested in all areas of technology, and devotes about 40% of its fund to healthcare. The firm’s investments interests are mostly in medical devices, diagnostics, instrumentation and services, but the firm will also consider investments in breakthrough therapeutic technologies, so long as these will not require lengthy clinical trials. The firm is also interested in novel healthcare IT opportunities such as applications of AI and machine learning in healthcare. The firm seeks highly differentiated, disruptive technology; and does not invest in “me-too” products. The firm primarily invests in companies with revenue-generating products.

The firm seeks disruptive technology companies led by high-quality management teams, and prefers to work with managers who have had previous successes in technology start-ups. The firm has a significant network in Europe and can help portfolio companies commercialize their products and services in European markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with a global presence invests in several verticals with the core interest being in scalable, breakthrough technologies. Initial investments may range from $100k – $1M, with up to $10M being invested over the life of the investment, in the form of convertible notes or straight equity. The firm will lead investments or co-invest as a syndicate. The firm will invest in companies on a global basis but is focused on companies in the U.S. and Canada. The partners and advisors of the fund look to add value to portfolio companies through an extensive international network and strong technical expertise.

The firm is generally agnostic to industry and is most interested in unique/novel technologies, with a special interest in AI and blockchain solutions in the healthcare space. While the group is primarily interested in software-based technologies, whether in drug discovery, enterprise software, digital health, etc., medical devices that do not require a traditional regulatory pathway (510(k) or PMA) and that have a core software component will also be considered.

The firm has no strict company or management team requirements and looks to mentor companies/management teams. The firm does not require a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.